Actinogen Medical Limited (ACW.XA)
| Previous close | 0.0290 |
| Open | 0.0295 |
| Bid | 0.0280 x N/A |
| Ask | 0.0300 x N/A |
| Day's range | 0.0290 - 0.0300 |
| 52-week range | 0.0150 - 0.0660 |
| Volume | |
| Avg. volume | 1,622,425 |
| Market cap | N/A |
| Beta (5Y monthly) | 2.28 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Enrolment completed in Actinogen's XanaCIDD phase 2a cognition & depression trial
Actinogen Medical Limited (ASX: ACW) announces the full enrolment of 167 participants in the Company's XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder (MDD). The XanaCIDD trial is a proof-of-concept, placebo-controlled, parallel group trial with a six-week treatment period and four weeks of follow up.
- PR Newswire
First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trial
Actinogen Medical Limited (ASX: ACW) announces that the first patient has been randomized and treated in the XanaMIA phase 2b clinical trial in patients with biomarker-positive mild to moderate Alzheimer's disease (AD). This represents the culmination of the site and screening setup phase of the trial when patient pre-screening for elevated levels of the pTau blood biomarker commenced at multiple clinical sites.
- PR Newswire
Positive Xanamem® human PET study published in the Journal of Alzheimer's Disease demonstrating robust CNS[1] target enzyme occupancy
Actinogen Medical Limited (ASX: ACW) announces that its human Positron Emission Tomography (PET) study, confirming high levels of Xanamem target occupancy in the brain at safe, well tolerated, and biologically active doses, has been published in the Journal of Alzheimer's Disease.
